PURPOSE Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis.
An enhanced understanding of the immune landscape of anatomically and molecularly …

Background Recently, immunotherapy with immune checkpoint inhibitors (ICIs) has shown
promising efficacy in biliary tract cancer (BTC), which includes gallbladder cancer (GBC) …

Background Biliary tract cancers (BTCs) are a heterogeneous group of aggressive, rare
malignancies with limited standard chemotherapeutic options for advanced disease. Recent …

Background Immune microenvironment is well recognized as a critical regulator across
cancer types, despite its complex roles in different disease conditions. Intrahepatic …

Biliary tract cancers (BTCs) are a group of rare cancers that account for up to 3–5% of
cancer patients worldwide. BTCs include cholangiocarcinoma (CCA), gallbladder cancer …

Background and Aims Cholangiocarcinoma (CCA) is a deadly and highly therapy‐refractory
cancer of the bile ducts, with early results from immune checkpoint blockade trials showing …

Remarkable advancements in techniques of genomic profiling and bioinformatics have led
to the accumulation of vast amounts of knowledge on the genomic profiles of biliary tract …

Intrahepatic cholangiocarcinoma (ICC) is a relatively rare but highly aggressive tumor type
that responds poorly to chemotherapy and immunotherapy. Comprehensive molecular …

Background Chemotherapy is a standard regimen for advanced or relapsed biliary tract
cancer (BTC) with a 5-year overall survival (OS) rate of approximately 5% and a median OS …

Biliary tract cancers (BTCs) are rare with poor prognosis. Due to the advent of genomic
sequencing, new data have emerged regarding the molecular makeup of this disease. To …